In the April 12 edition of the New England Journal of Medicine The results appear.

ALL induction treatment failing should not be a computerized indication for bone marrow transplant International study that included St. Jude Children’s Research Hospital reports some young acute lymphoblastic leukemia individuals who fail induction therapy can perform high cure prices without bone marrow transplantation. An international study discovered that bone marrow transplants aren’t the best option for a few young patients with severe lymphoblastic leukemia who neglect to attain clinical remission after the preliminary weeks of extreme chemotherapy referred to as induction therapy .

I am gratified to be involved in this medical trial, that will potentially bring ART-123 one step nearer to patients suffering from severe sepsis. The initiation of this large, multi-center trial is a significant milestone for AKP America as we move closer to potential commercialization in the United States. The strong product sales of this drug in japan market demonstrate not merely the clinical need for ART-123, but also its market potential, said Mr. Naoyuki Ono, President and Chief Executive Officer of AKP America.. AKP America commences ART-123 Phase 3 trial in severe sepsis patients with coagulopathy Asahi Kasei Pharma America Corp. The Phase 3 trial follows an effective 750-individual randomized, double-blind, placebo-controlled Phase 2b study that assessed the efficacy and safety of ART-123.